Capsule formulations to improve delivery of poorly absorbable drugs

Webcast

Wednesday March 2, 2022 at 11am EST | 4pm GMT | 5pm CET Compounds that are poorly soluble in water are still prevalent in the pharmaceutical industry drug development pipeline. Enabling technologies such as lipid-based formulations (LBF) and amorphous solid dispersions (ASDs) can address these bioavailability limitations, enabling the creation of effective drug products.

Register free: ​ https://www.pharmtech.com/pt_w/absorbable

Event Overview:

Compounds that are poorly soluble in water are still prevalent in the pharmaceutical industry drug development pipeline. Enabling technologies such as lipid-based formulations (LBF) and amorphous solid dispersions (ASDs) can address these bioavailability limitations, enabling the creation of effective drug products. Capsule-based dosage forms are ideal in these circumstances. Depending on the type of capsule shell selected, they can be filled with a liquid LBF, they can ensure the long-term stability of ASDs, and even promote in situ prolonged drug absorption. Lonza Capsule Applications Services lab offers ways to address drug solubility limitations, develop innovative capsules to tailor drug delivery, and optimize encapsulation processes.

Key Learning Objectives:

  • Find out about the classification, main attributes and the available encapsulation technologies for lipid-based formulations;
  • Learn the main attributes of amorphous solid dispersions, and how capsules can increase their efficiency;
  • Discover the new Lonza Capsule Applications Services lab that offers ways to address drug solubility limitations, and speed up formulation and encapsulation process development.

Who Should Attend:

  • Scientist, Senior Scientist, Principal Scientist
  • Preformulation, Formulation, Engineering, Drug Delivery
  • Project manager
  • CMC manager

Speakers

Vincent Jannin
Head of Capsule Applications Services
Lonza Capsules & Health Ingredients

Dr. Vincent Jannin is Head of Capsule Applications Services at Lonza CHI. Previously, he held diverse positions up to Research Director at Gattefossé and was lecturer at Lyon University.

Vincent earned his Pharm.D. and Ph.D. in Pharmaceutical Technology from the University of Bourgogne, and received his habilitation (HDR) from the University of Lyon. Vincent has published more than 140 peer-reviewed papers and given more than 60 lectures on Drug Delivery Systems.

David Lyon
Senior Fellow, Global R&D
Lonza Small Molecules


David Lyon serves as a Senior Fellow, Global R&D, at Lonza’s site in Bend, Oregon, USA, where he advises on internal and external collaborations for bioavailability enhancement technologies, modified release, and bioprocessing. David joined Bend Research as a Research Chemist in 1991. During his tenure at Bend Research, he held positions of increasing responsibility, leading numerous large-scale research programs and ultimately being named Senior Vice President, Research prior to the company’s acquisition by Capsugel and, subsequently, Lonza. His areas of expertise include extensive work with amorphous solid dispersions for bioavailability enhancement of active compounds with low aqueous solubility, as well as the development of modified release formulations and bioprocesses. David received his Bachelor of Science degree in Chemistry from Western Washington University and his Ph.D. in Inorganic Chemistry from the University of Oregon. Subsequently, he completed postdoctoral work at the California Institute of Technology.

Register free: https://www.pharmtech.com/pt_w/absorbable